This webinar will provide a look at how the Institute of Hematopathology in Hamburg, Germany, is implementing complex genomic testing for lung cancer.
Lung cancer has become a prime example of the success of molecularly stratified therapies. A steady increase of therapeutically relevant biomarkers has underlined the need for complex diagnostic assays like hybrid capture next-generation sequencing (HC-NGS) technology, which allows for simultaneous detection of single nucleotide variants, insertions/deletions, copy number variants, and translocations on limited biopsy material.
The resulting information on tumor genotype is extensive, however, and requires sophisticated bioinformatic tools and experienced molecular biologists to precisely distinguish relevant alterations with likely pathological outcome from artefacts or polymorphisms. Reliable software solutions are required to aid precise pathological reporting and provide information on the appropriate biomarker-guided therapies as well as relevant supporting studies.
In this webinar, Dr. Markus Falk and Dr. Daniela Stefanie Schmidt from the Institute of Hematopathology will outline a study they performed to evaluate the Roche Diagnostics AVENIO Tumor Tissue Analysis Kit, an HC-NGS assay that includes 77 genes for expanded tumor profiling, on 24 lung cancer samples with known genotype.
Drs. Falk and Schmidt also discuss their use of Roche's NAVIFY Mutation Profiler software platform for pathological reporting. They will detail how they evaluated the platform for feasibility, accuracy, and the potential to save time in report generation.